- -- 19 October 2010
- Cancer Research UK and immatics biotechnologies commence trial for brain cancer vaccine
- -- 21 September 2010
- immatics raises €54 million to advance its late stage clinical therapeutic cancer vaccine portfolio
- -- 20 September 2010
- Updated survival data from IMA901 Phase II study will be presented at the 35th ESMO Congress in Milan (October 8-12)
- -- 05 June 2010
- immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell Carcinoma at ASCO
- -- 05 June 2010
- IMA901 data poster presented at ASCO Annual Meeting available for download now!
- -- 02 June 2010
- immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
- -- 17 May 2010
- IMA901 Phase II data presented at ASCO Annual Meeting in Chicago (June, 4-8)
- -- 17 May 2010
- Progress in preclinical projects presented at CIMT Annual Meeting (May, 26-28)
- -- 21 April 2010
- AACR Annual Meeting 2010 posters now available for download
- -- 16 February 2010
- immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
Cancer Research UK and immatics biotechnologies commence trial for brain cancer vaccine
Today Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm – announced that together with immatics biotechnologies they have commenced the first clinical trial of a promising cancer vaccine to treat glioblastoma, one of the most common forms of brain cancer.
For more information please find the complete press release here!